Drug Profile
Omapatrilat
Alternative Names: BMS 186716; BMS 186716-01; VanlevLatest Information Update: 10 Jan 2007
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihypertensives; Pyridines; Small molecules; Thiazepines
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Heart failure; Hypertension; Myocardial infarction
Most Recent Events
- 26 May 2003 Data presented at the 18th Annual meeting of the American Society of Hypertention (ASH-2003) have been added to the Hypertension pharmacodynamics section
- 15 Oct 2002 The FDA have issued Bristol-Myers Squibb with an action letter regarding approval of Vanlev®
- 24 Sep 2002 A study has been added to the adverse events and Heart Failure therapeutic trials sections